Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis.

Neurobiology of aging | 2011

Alzheimer's disease (AD) can present with non-amnestic clinical syndromes. We investigated whether there is an imaging signature of AD pathology in these atypical subjects. We identified 14 subjects that had pathological AD, a non-amnestic presentation (i.e. atypical AD), and MRI. These subjects were matched to 14 with clinical and pathological AD (i.e. typical AD), 14 with the same non-amnestic presentations with frontotemporal lobar degeneration (FTLD) pathology, and 20 controls. Voxel-based morphometry and region-of-interest (ROI) analysis were used to assess patterns of grey matter loss. Loss was observed in the temporoparietal cortex in both typical and atypical AD, and showed significantly greater loss than FTLD. However, the medial temporal lobes were more severely affected in typical AD and FTLD compared to atypical AD. A ratio of hippocampal and temporoparietal volumes provided excellent discrimination of atypical AD from FTLD subjects. Temporoparietal atrophy may therefore provide a useful marker of the presence of AD pathology even in subjects with atypical clinical presentations, especially in the context of relative sparing of the hippocampus.

Pubmed ID: 19914744 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCRR NIH HHS, United States
    Id: C06 RR018898
  • Agency: NIA NIH HHS, United States
    Id: P50 AG016574
  • Agency: NICHD NIH HHS, United States
    Id: HD49078
  • Agency: NINDS NIH HHS, United States
    Id: L30 NS056807-02
  • Agency: NIA NIH HHS, United States
    Id: R01-AG11378
  • Agency: NIA NIH HHS, United States
    Id: R01 AG011378
  • Agency: NIA NIH HHS, United States
    Id: P50-AG16574
  • Agency: NINDS NIH HHS, United States
    Id: L30 NS056807-01
  • Agency: NINDS NIH HHS, United States
    Id: L30 NS056807
  • Agency: NICHD NIH HHS, United States
    Id: K12 HD049078
  • Agency: NIA NIH HHS, United States
    Id: U01-AG06786
  • Agency: NIA NIH HHS, United States
    Id: U01 AG006786

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


University of Pittsburgh Alzheimer Disease Research Center (tool)

RRID:SCR_008084

A research center associated with the University of Pittsburgh that specializes in the diagnosis of Alzheimer's disease and related disorders. The overall objective of the ADRC is to study the pathophysiology of Alzheimer's disease, with the aim of improving the reliability of diagnosis of Alzheimer's and developing effective treatment strategies. Current research foci emphasize neuropsychiatry and neuropsychology, molecular genetics and epidemiology, basic neuroscience, and structural and functional imaging that aid in the diagnosis and treatment of Alzheimer's disease. Specific services at the ADRC include: comprehensive diagnostic evaluation of patients with suspected Alzheimer's disease and other forms of dementia; evaluation of memory, language, judgment, and other cognitive abilities; and education and counseling for patients and families.

View all literature mentions